Related Experiment Video
Updated: Jun 10, 2025
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBM
Michal Nisnboym1,2,3, Chaim T Sneiderman1, Ambika P Jaswal1
1Department of Neurological Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Background:
Glioblastoma (GBM) is an aggressive cancer with limited treatment options. Immunotherapy targeting CD69, an early activation marker on T cells, has shown promise in preclinical models of non-CNS malignancies. This study investigates anti-CD69 therapy alone or in combination with anti-PD-1 in a preclinical GBM model.
Research Design And Methods:
CD69 expression in GBM patient tissues was analyzed using the TCGA database. Therapeutic efficacy of anti-CD69 was tested in a murine GBM model with different regimens. Immune cell populations in the tumor microenvironment (TME) were assessed by flow cytometry.
Results:
Increased CD69 expression was observed in GBM patients compared to normal brain tissue and was associated with worse prognosis. Anti-CD69 treatment reduced percentages of CD69+ immune cells but did not improve survival in GBM-bearing mice. Increased PD-1 expression on NK cells was observed following anti-CD69 treatment. Anti-CD69 treatment was not improved by the addition of anti-PD-1 in vivo.
Conclusions:
This is the first study evaluating anti-CD69 therapy in a preclinical GBM model. Despite promising preclinical data in other cancers, anti-CD69 monotherapy or combination therapy with anti-PD-1 did not improve survival in this GBM model.
Insights
Investigating anti-CD69 immunotherapy for glioblastoma (GBM) revealed increased CD69 expression in patients. However, anti-CD69 therapy alone or with anti-PD-1 did not improve survival in a preclinical GBM model.
Area of Science:
- Immunology
- Oncology
- Neuro-oncology
Background:
- Glioblastoma (GBM) is an aggressive brain cancer with poor treatment outcomes.
- CD69, an early T cell activation marker, shows therapeutic potential in preclinical models of other cancers.
- Investigating anti-CD69 therapy in GBM is crucial due to limited treatment options.
Purpose of the Study:
- To evaluate the efficacy of anti-CD69 immunotherapy in a preclinical glioblastoma model.
- To assess the combination therapy of anti-CD69 and anti-PD-1 for GBM treatment.
- To analyze CD69 expression in GBM patients and its correlation with prognosis.
Main Methods:
- CD69 expression analysis in GBM patient tissues using TCGA database.
- Therapeutic efficacy testing of anti-CD69 in a murine GBM model.
- Assessment of immune cell populations within the tumor microenvironment via flow cytometry.
Main Results:
- Elevated CD69 expression observed in GBM patients, correlating with a worse prognosis.
- Anti-CD69 treatment decreased CD69+ immune cells but did not enhance survival in mice.
- Increased PD-1 expression on NK cells noted post-anti-CD69 treatment; combination therapy showed no survival benefit.
Conclusions:
- This study is the first to evaluate anti-CD69 therapy in a preclinical GBM model.
- Anti-CD69 monotherapy and combination with anti-PD-1 failed to improve survival in this GBM model.
- Preclinical efficacy of anti-CD69 in other cancers does not translate to improved survival in GBM.
